These drug reviews aim to give objective information and guidance including efficacy, adverse effects, place in treatment and arrangements for prescribing to commissioners of health services, prescribers and others. The drugs are often not yet licensed for the indication. The reports are prepared by a multidisciplinary team within the RDTC and reviewed by health authority personnel and appropriate external specialists. However, the responsibility for the content and conclusions rests solely with the RDTC.
This information is produced for use by NHS healthcare professionals. See site disclaimer.
New documents are restricted to stakeholders only for a period of 3 months following publication